We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.38%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.47B
AUM Growth
+$39M
Cap. Flow
-$32.3M
Cap. Flow %
-2.19%
Top 10 Hldgs %
26.19%
Holding
101
New
9
Increased
29
Reduced
33
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$21.4M
2
PFE icon
Pfizer
PFE
+$19.4M
3
VEEV icon
Veeva Systems
VEEV
+$17.8M
4
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$11.9M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$11.6M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13M
3
LIVN icon
LivaNova
LIVN
+$11.9M
4
NVCR icon
NovoCure
NVCR
+$11.7M
5
CNC icon
Centene
CNC
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 94.98%
2 Industrials 1.94%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$376B
$50.1M 3.4%
125,000
+12,000
+11% +$4.78M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$49.2M 3.34%
525,000
-70,000
-12% -$6.44M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$121B
$43.5M 2.95%
215,897
+47,476
+28% +$9.93M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.9B
$39.1M 2.65%
220,000
-30,000
-12% -$5.2M
ELV icon
5
Elevance Health
ELV
$81.5B
$36.3M 2.46%
95,000
– –
ABBV icon
6
AbbVie
ABBV
$443B
$36M 2.45%
320,000
-48,000
-13% -$5.41M
TDOC icon
7
Teladoc Health
TDOC
$1.22B
$34.9M 2.37%
210,000
+20,000
+11% +$3.24M
MDT icon
8
Medtronic
MDT
$109B
$33.9M 2.3%
273,000
-62,000
-19% -$7.78M
CVS icon
9
CVS Health
CVS
$133B
$31.7M 2.15%
380,000
-70,000
-16% -$5.73M
BIIB icon
10
Biogen
BIIB
$30B
$31.2M 2.12%
90,000
+70,500
+362% +$21.4M
CI icon
11
Cigna
CI
$73.7B
$30.9M 2.1%
130,500
+20,500
+19% +$5.12M
ABT icon
12
Abbott
ABT
$183B
$29M 1.97%
250,000
-25,000
-9% -$2.91M
LLY icon
13
Eli Lilly
LLY
$1.02T
$27.3M 1.85%
118,800
-51,200
-30% -$10.3M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$26.7M 1.81%
165,000
+15,000
+10% +$2.41M
NVCR icon
15
NovoCure
NVCR
$1.73B
$26.6M 1.81%
120,000
-60,000
-33% -$11.7M
TMO icon
16
Thermo Fisher Scientific
TMO
$213B
$25.2M 1.71%
50,000
+5,000
+11% +$2.36M
XLRN
17
DELISTED
Acceleron Pharma
XLRN
$25.1M 1.7%
200,000
+40,000
+25% +$5.04M
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
$24.9M 1.69%
157,925
+77,925
+97% +$11.6M
HUM icon
19
Humana
HUM
$43.7B
$24.4M 1.65%
55,000
-14,000
-20% -$6.12M
AXNX
20
DELISTED
Axonics, Inc. Common Stock
AXNX
$24.1M 1.64%
380,000
-30,000
-7% -$1.77M
MRK icon
21
Merck
MRK
$322B
$23.3M 1.58%
300,000
+17,040
+6% +$1.27M
VEEV icon
22
Veeva Systems
VEEV
$33.1B
$23.3M 1.58%
75,000
+64,000
+582% +$17.8M
ALNY icon
23
Alnylam Pharmaceuticals
ALNY
$27.5B
$22.9M 1.55%
135,000
– –
ZBH icon
24
Zimmer Biomet
ZBH
$18.2B
$22.5M 1.53%
144,200
+10,300
+8% +$1.67M
BSX icon
25
Boston Scientific
BSX
$69.5B
$22.2M 1.51%
520,000
-150,000
-22% -$6.31M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rhenman & Partners Asset Management held 101 positions worth $1.47B, up 2.7% from $1.43B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management's Q2 2021 filing shows 9 new, 29 increased, 33 reduced and 7 closed positions. Its largest new stake was Pfizer: 500,000 shares worth $19.6M. The largest sale was Johnson & Johnson, an estimated $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Rhenman & Partners Asset Management's largest Q2 2021 buy was Pfizer: 500,000 shares worth $19.6M.
  • Rhenman & Partners Asset Management added most to Biogen in Q2 2021, an estimated $21.4M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2021 reduction was Johnson & Johnson, cutting an estimated $41.4M.
  • Rhenman & Partners Asset Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $6.41M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $1.47B portfolio in Q2 2021.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 7 in Q2 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 2.7% quarter-over-quarter to $1.47B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.